{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:41:04Z","timestamp":1790721664660,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.clinthera.2005.11.015","type":"journal-article","created":{"date-parts":[[2005,12,22]],"date-time":"2005-12-22T23:48:05Z","timestamp":1135295285000},"page":"1725-1751","source":"Crossref","is-referenced-by-count":61,"title":["Cinacalcet: An oral calcimimetic agent for the managementof hyperparathyroidism"],"prefix":"10.1016","volume":"27","author":[{"given":"Betty J.","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.11.015_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1774-9987.2005.00208.x","article-title":"Challenges in the therapy of secondary hyperparathyroidism","volume":"9","author":"Wood","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.clinthera.2005.11.015_bib2","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2005.11.015_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jc.86.2.485","article-title":"Clinical review 122: Parathyroid carcinoma","volume":"86","author":"Shane","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2005.11.015_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0272-6386(97)90330-9","article-title":"The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure","volume":"29","author":"Martinez","year":"1997","journal-title":"AmJ Kidney Dis"},{"key":"10.1016\/j.clinthera.2005.11.015_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2005.11.015_bib6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib7","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199507203330307","article-title":"Renal osteodystrophy","volume":"333","author":"Hruska","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.11.015_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00041552-200307000-00007","article-title":"Renal bone disease: A new conceptual framework for the interpretation of bone histomorphometry","volume":"12","author":"Parfitt","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.clinthera.2005.11.015_bib10","series-title":"Presented at: 41 st Congress of the European Renal Association and the European Dialysis and Transplant Association","article-title":"Association of elevated serum parathyroid hormone (PTH) and calcium with risk of hip, vertebral, or pelvic fracture in hemodialysis patients","author":"Kim","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.11.015_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","article-title":"Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product","volume":"23","author":"Moe","year":"2003","journal-title":"Am J Nephrol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.11.015_bib13","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2005.11.015_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKFK\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2005.11.015_bib15","first-page":"270A","article-title":"Achievement of proposed NKF-K\/DOQI bone metabolism and disease guidelines: Results from the dialysis outcomes and practice pattern study (DOPPS)","volume":"13","author":"Kim","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10408360590886606","article-title":"The calcium sensing receptor in normal physiology and pathophysiology: A review","volume":"42","author":"Tfelt-Hansen","year":"2005","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.clinthera.2005.11.015_bib17","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00302.2004","article-title":"The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism","volume":"288","author":"Rodriguez","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib18","series-title":"Sensipar [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2005.11.015_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2005.11.015_bib21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfh925","article-title":"Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism","volume":"20","author":"Serra","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2005.11.015_bib22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/ndt\/gfh924","article-title":"The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism","volume":"20","author":"Kruse","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2005.11.015_bib23","first-page":"4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor","volume":"95","author":"Nemeth","year":"1998"},{"key":"10.1016\/j.clinthera.2005.11.015_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ceca.2003.10.020","article-title":"Calcimimetic and calcilytic drugs: Just for parathyroid cells?","volume":"35","author":"Nemeth","year":"2004","journal-title":"Cell Calcium"},{"key":"10.1016\/j.clinthera.2005.11.015_bib25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1471-4892(02)00210-2","article-title":"Calcimimetics: Therapeutic potential in hyperparathyroidism","volume":"2","author":"Cohen","year":"2002","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2005.11.015_bib27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","article-title":"Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism","volume":"67","author":"Colloton","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2005.11.015_bib28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/ndt\/gfh834","article-title":"1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar\/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism","volume":"20","author":"Henley","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2005.11.015_bib29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2125.2004.02088.x","article-title":"The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis","volume":"57","author":"Ohashi","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib30","doi-asserted-by":"crossref","first-page":"P62","DOI":"10.1016\/j.clpt.2003.11.236","article-title":"A population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of cinacalcet HCl in renal-dialysis patients with secondary hyperparathyroidism(HPT)","volume":"75","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.11.015_bib31","first-page":"P91","article-title":"Pharmacokinetics (PK) of calcimimetic AMG073 in secondary hyper-parathyroidism (SHPT)","volume":"69","author":"Wang","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.11.015_bib32","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1124\/dmd.104.000604","article-title":"Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models","volume":"32","author":"Kumar","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2005.11.015_bib33","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2005.11.015_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200544050-00004","article-title":"No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar\/Mimpara)","volume":"44","author":"Padhi","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2005.11.015_bib35","first-page":"211","article-title":"In vitro metabolism of cinacalcet HCl (AMG073\/KRN1493), a new calcimimetic agent, in human liver microsomes and cytochrome P450 isoforms","volume":"36","author":"Nakashima","year":"2004","journal-title":"Drug Metab Rev"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.11.015_bib36","first-page":"149","article-title":"The impact of hepatic impairment on the pharmacokinetics of cinacalcet HCl","volume":"18","author":"Harris","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2005.11.015_bib37","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2005.11.015_bib39","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib40","first-page":"463A","article-title":"Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl","volume":"14","author":"Moe","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.11.015_bib41","first-page":"150","article-title":"Sustained, long-term reductions in parathyroid hormone (PTH) after 3 years of treatment with the calcimimetic cinacalcet HCl in patients withsecondary hyperparathyroidism (SHPT)","volume":"18","author":"Cunningham","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2005.11.015_bib42","doi-asserted-by":"crossref","first-page":"V27","DOI":"10.1093\/ndt\/gfh1053","article-title":"Clinical experience with cinacalcet HCl","volume":"19","author":"Urena Torres","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.11.015_bib43","first-page":"151","article-title":"Sustained control of uremic secondary hyperparathyroidism after three years of treatment with the calcimimetic cinacalcet HCl: A single center experience","volume":"18","author":"Urena","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2005.11.015_bib44","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.11.015_bib45","first-page":"461A","article-title":"Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (HPT)","volume":"14","author":"Block","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib46","first-page":"461A","article-title":"Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): Results of a European\/Australianphase 3 study","volume":"14","author":"de Francisco","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib47","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib48","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"Cinacalcet HCl (Sensipar\u2122) for the management of secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD)","author":"Mittman","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib49","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"Cinacalcet HCl (Sensipar\u2122) effectively manages secondary hyperparathyroidism in new to dialysis patients","author":"Goodman","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib50","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"Cinacalcet HCl (Sensipar\u2122) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis","author":"Goodman","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib51","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"Long-term treatment of secondary hyperparathyroidism (HPT) with cinacalcet HCl (Sensipar\u2122) in patients receiving dialysis","author":"Sterrett","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib52","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"Maintenance of NKF-K\/DOQITM goals for parathyroid hor mone and Ca x P with cinacalcet HCl","author":"Sprague","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib53","first-page":"464A","article-title":"Cinacalcet HCl controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis","volume":"14","author":"Coyne","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib54","first-page":"463A","article-title":"Cinacalcet HCl controls secondary hyperparathyroidism (HPT) in dialysis patients regardless of disease severity","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib55","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"The CONTROL STUDY: Enhanced achievement of NKF-K\/DOQITM bone metabolism and disease targets using cinacalcet HCl (Sensipar)","author":"Reed","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib56","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"Preliminary results from TARGET: Treatment strategies to achieve recom mended K\/DOQITM goals in ESRD patients on cinacalcet","author":"Chertow","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib57","first-page":"572A","article-title":"The effects of one-year treatment with the calcimimetic AMG 073 on bone health in ESRD patients with secondary hyperparathyroidism (SHPT)","volume":"13","author":"Quarles","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib58","series-title":"Presented at: 41st Congress of the European Renal Association and the European Dialysis and Transplant Association","article-title":"Cinacalcet HCl reduces bone turnover and bone mar row fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT)","author":"Malluche","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib59","series-title":"Presented at: American Society of Nephrology Renal Week","article-title":"Effects of cinacalcet on 1-84 PTH and 7-84 PTH","author":"Amerling","year":"2004"},{"key":"10.1016\/j.clinthera.2005.11.015_bib60","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ndt\/gfh829","article-title":"Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism","volume":"20","author":"Lien","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2005.11.015_bib61","first-page":"5171","article-title":"The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX","volume":"18","author":"Silverberg","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.015_bib62","first-page":"S103","article-title":"Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma","volume":"19","author":"Silverberg","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.015_bib63","first-page":"S392","article-title":"Effective management of severe hypercalcemia with the calcimimetic cinacalcet HCl in patients with parathyroid carcinoma","volume":"18","author":"Rubin","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2005.11.015_bib64","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jc.83.4.1083","article-title":"Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent","volume":"83","author":"Collins","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2005.11.015_bib65","first-page":"461A","article-title":"Cinacalcet HCl absorption in study subjects is not affected by coadministration of medications commonly prescribed to chronic kidney disease (CKD) patients (pantoprazole, sevelamer HCl, and calcium carbonate)","volume":"14","author":"Padhi","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5414\/CNP57131","article-title":"Calcium-sensing receptor gene polymorphism affects the parathyroid response to moderate hypercalcemic suppression in patients with end-stage renal disease","volume":"57","author":"Yokoyama","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clinthera.2005.11.015_bib67","first-page":"29","article-title":"Calcium-sensing receptor gene polymorphism Arg990G1y and its possible effect on response to cinacalcet HCl","volume":"15","author":"Rothe","year":"2005","journal-title":"PharmacogenetGenomics"},{"key":"10.1016\/j.clinthera.2005.11.015_bib68","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2005.11.015_bib69","doi-asserted-by":"crossref","first-page":"V9","DOI":"10.1093\/ndt\/gfh1050","article-title":"Achieving therapeutic targets in the treatment of secondary hyperparathyroidism","volume":"19","author":"Cunningham","year":"2004","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805002948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805002948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T22:57:38Z","timestamp":1626908258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805002948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0149291805002948"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.11.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}